Trademark: 88470736
Status Date
Thursday, June 22, 2023
Filing Date
Wednesday, June 12, 2019
Published for Opposition
Tuesday, November 3, 2020
40 Providing technical information in the field of pharmaceutical manufacturing; custom manufacture of pharmaceuticals; providing information about custom manufacturing of pharmaceuticals in the nature of oral, inhalatory, intramuscular, intraperitoneal, intratracheal, intratumoral, intravenous, subcutaneous, and topical applied aggregations of liposomes providing time-release of encapsulated pharmaceuticals made to the order or specification of others, for treatment of a wide variety of diseases; custom manufacturing of pharmaceuticals in the nature of oral, inhalatory, intramuscular, intraperitoneal, intratracheal, intratumoral, intravenous, subcutaneous, and topical applied aggregations of liposomes providing time-release of encapsulated pharmaceuticals made to the order or specification of others, for treatment of a wide variety of diseases
5 Nanomedicinal products for medical purposes, namely, organic and inorganic pharmaceutical preparations, nanoparticle pharmaceutical preparations, nutraceuticals, pharmaceuticals, pharmaceutical preparations and substances for the prevention and treatment of cancer, diabetes, infectious diseases, autoimmune diseases and disorders, orthopedic diseases and disorders, blood diseases and disorders, fungal infections, diseases and disorders of the central nervous system, oncological diseases and disorders, and ophthalmological diseases and disorders; chemical preparations for pharmaceutical and medical purposes, namely, for the prevention and treatment of cancer, diabetes, infectious diseases, autoimmune diseases and disorders, orthopedic diseases and disorders, blood diseases and disorders, fungal infections, diseases and disorders of the central nervous system, oncological diseases and disorders, and ophthalmological diseases and disorders; chemical reagents for medical purposes; clinical medical reagents; drug delivery agents in the form of nanoparticle powders that facilitate the delivery of pharmaceutical preparations; liposomal nanoparticle powders being drug delivery agents to facilitate delivery of genetic material and vaccines for medical purposes; all of the aforementioned for human or animal use
44 Medical services, namely, administration of nanomedicinal medications; medical services, namely, medical consultancy relating to nanomedicinal products
42 Drug discovery services; pharmaceutical research and development; research and development of nanomedicinal products; scientific and medical research and development for nutraceuticals, pharmaceuticals, pharmaceutical preparations and substances in the field of cancer, diabetes, infectious diseases, autoimmune diseases and disorders, orthopedic diseases and disorders, blood diseases and disorders, fungal infections, diseases and disorders of the central nervous system, oncological diseases and disorders, and ophthalmological diseases and disorders; scientific research and development for pharmaceuticals in the nature of oral, inhalatory, intramuscular, intraperitoneal, intratracheal, intratumoral intravenous, subcutaneous, and topical applied aggregations of liposomes providing time-release of encapsulated pharmaceuticals, for treatment of a wide variety of diseases; providing medical and scientific information in the aforementioned fields
Jan 5, 2024
Case Assigned To Intent To Use Paralegal
Dec 28, 2023
Teas Statement Of Use Received
Jun 23, 2023
Notice Of Approval Of Extension Request E-Mailed
Jun 22, 2023
Sou Extension 5 Granted
Jun 15, 2023
Sou Extension 5 Filed
Jun 22, 2023
Case Assigned To Intent To Use Paralegal
Jun 15, 2023
Sou Teas Extension Received
Dec 10, 2022
Notice Of Approval Of Extension Request E-Mailed
Dec 8, 2022
Sou Extension 4 Granted
Dec 8, 2022
Sou Extension 4 Filed
Dec 8, 2022
Sou Teas Extension Received
Oct 26, 2022
Assignment Of Ownership Not Updated Automatically
May 20, 2022
Notice Of Approval Of Extension Request E-Mailed
May 18, 2022
Sou Extension 3 Granted
May 18, 2022
Sou Extension 3 Filed
May 18, 2022
Sou Teas Extension Received
Dec 23, 2021
Notice Of Approval Of Extension Request E-Mailed
Dec 21, 2021
Sou Extension 2 Granted
Dec 21, 2021
Sou Extension 2 Filed
Dec 21, 2021
Sou Teas Extension Received
Jun 29, 2021
Notice Of Approval Of Extension Request E-Mailed
Jun 25, 2021
Sou Extension 1 Granted
Jun 25, 2021
Sou Extension 1 Filed
Jun 25, 2021
Sou Teas Extension Received
Dec 29, 2020
Noa E-Mailed - Sou Required From Applicant
Nov 3, 2020
Official Gazette Publication Confirmation E-Mailed
Nov 3, 2020
Published For Opposition
Oct 14, 2020
Notification Of Notice Of Publication E-Mailed
Sep 25, 2020
Exparte Appeal Terminated
Sep 25, 2020
Approved For Pub - Principal Register
Sep 25, 2020
Teas/Email Correspondence Entered
Sep 25, 2020
Correspondence Received In Law Office
Sep 25, 2020
Assigned To Lie
Sep 23, 2020
Teas Request For Reconsideration Received
Sep 23, 2020
Ex Parte Appeal-Instituted
Sep 23, 2020
Jurisdiction Restored To Examining Attorney
Sep 23, 2020
Exparte Appeal Received At Ttab
Jul 28, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Jul 28, 2020
Teas Change Of Correspondence Received
Jul 28, 2020
Teas Change Of Owner Address Received
Apr 1, 2020
Notification Of Final Refusal Emailed
Apr 1, 2020
Final Refusal E-Mailed
Apr 1, 2020
Final Refusal Written
Mar 10, 2020
Teas/Email Correspondence Entered
Mar 9, 2020
Correspondence Received In Law Office
Mar 9, 2020
Teas Response To Office Action Received
Sep 12, 2019
Notification Of Non-Final Action E-Mailed
Sep 12, 2019
Non-Final Action E-Mailed
Sep 12, 2019
Non-Final Action Written
Sep 4, 2019
Assigned To Examiner
Aug 14, 2019
Automatic Update Of Assignment Of Ownership
Jun 25, 2019
New Application Office Supplied Data Entered
Jun 15, 2019
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
